The protease-activated receptor-2-specific agonists 2-aminothiazol-4-yl- LIGRL-NH₂and 6-aminonicotinyl-LIGRL-NH₂ stimulate multiple signaling pathways to induce physiological responses in vitro and in vivo

Protease-activated receptor-2 (PAR₂) is one of four protease-activated G-protein-coupled receptors. PAR₂ is expressed on multiple cell types where it contributes to cellular responses to endogenous and exogenous proteases. Proteolytic cleavage of PAR₂ reveals a tethered ligand that activates PAR₂ and two major downstream signaling pathways: mitogen-activated protein kinase (MAPK) and intracellular Ca ²⁺ signaling. Peptides or peptidomimetics can mimic binding of the tethered ligand to stimulate signaling without the nonspecific effects of proteases. The most commonly used peptide activators of PAR₂ (e.g. SLIGRL-NH₂ and SLIGKV-NH₂) lack potency at the receptor. However, although the potency of 2-furoyl-LIGRLO-NH₂ (2-f-LIGRLO-NH₂) underscores the use of peptidomimetic PAR ₂ ligands as a mechanism to enhance pharmacological action at PAR₂, 2-f-LIGRLO-NH₂ has not been thoroughly evaluated. We evaluated the known agonist 2-f-LIGRLO-NH₂ and two recently described pentapeptidomimetic PAR₂-specific agonists, 2-aminothiazol-4-yl-LIGRL-NH₂ (2-at-LIGRL-NH₂) and 6-aminonicotinyl-LIGRL-NH₂ (6-an-LIGRL-NH₂). All peptidomimetic agonists stimulated PAR₂-dependent in vitro physiological responses, MAPK signaling, and Ca²⁺ signaling with an overall rank order of potency of 2-f-LIGRLO-NH₂ ≈ 2-at-LIGRL-NH₂ > 6-an-LIGRL-NH₂ ≫ SLIGRL-NH ₂. Because PAR₂ plays a major role in pathological pain conditions and to test potency of the peptidomimetic agonists in vivo, we evaluated these agonists in models relevant to nociception. All three agonists activated Ca²⁺ signaling in nociceptors in vitro, and both 2-at-LIGRL-NH₂ and 2-f-LIGRLO-NH₂ stimulated PAR ₂-dependent thermal hyperalgesia in vivo. We have characterized three high potency ligands that can be used to explore the physiological role of PAR₂ in a variety of systems and pathologies.